keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer survival

keyword
https://www.readbyqxmd.com/read/29790667/differences-in-cancer-survival-among-white-and-black-cancer-patients-by-presence-of-diabetes-mellitus-estimations-based-on-seer-medicare-linked-data-resource
#1
Clara Lam, Kathleen Cronin, Rachel Ballard, Angela Mariotto
Diabetes prevalence and racial health disparities in the diabetic population are increasing in the US. Population-based cancer-specific survival estimates for cancer patients with diabetes have not been assessed. The Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage provided data on cancer-specific deaths and diabetes prevalence among 14 separate cohorts representing 1 068 098 cancer patients ages 66 +  years diagnosed between 2000 and 2011 in 17 SEER areas. Cancer-specific survival estimates were calculated by diabetes status adjusted by age, stage, comorbidities, and cancer treatment, and stratified by cancer site and sex with whites without diabetes as the reference group...
May 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29790383/focal-treatment-for-unilateral-prostate-cancer-using-hifu-a-comprehensive-study-of-pooled-data
#2
Simone Albisinni, Christian Melot, Fouad Aoun, Ksenija Limani, Alexandre Peltier, Pascal Rischmann, Roland van Velthoven
BACKGROUND: Focal therapy for prostate cancer (PCa) remains experimental. Aim of the current study is to review available evidence and perform a pooled analysis exploring oncologic and functional results of High Intensity Focal Ultrasound (HIFU) focal therapy for the treatment of unilateral PCa. METHODS: The National Library of Medicine Database was searched for relevant articles. A wide search was performed including the combination of following words: "HIFU", "prostate", "cancer", "focal"...
May 23, 2018: Journal of Endourology
https://www.readbyqxmd.com/read/29789764/a-single-institution-analysis-of-low-dose-rate-brachytherapy-5-year-reported-survival-and-late-toxicity-outcomes
#3
REVIEW
Michael Chao, Sandra Spencer, Mario Guerrieri, Wei Ding, Mehran Goharian, Huong Ho, Michael Ng, Danielle Healey, Alwin Tan, Chee Cham, Daryl Lim Joon, Nathan Lawrentschuk, Douglas Travis, Shomik Sengupta, Yee Chan, Andrew Troy, Trung Pham, David Clarke, Peter Liodakis, Damien Bolton
Purpose: To report the 5-year biochemical relapse-free survival (BRFS), overall survival (OS), and long-term toxicity outcomes of patients treated with low-dose-rate (LDR) brachytherapy as monotherapy for low- to intermediate-risk prostate cancer. Material and methods: Between 2004 and 2011, 371 patients were treated with LDR brachytherapy as monotherapy. Of these, 102 patients (27%) underwent transurethral resection of the prostate (TURP) prior to implantation...
April 2018: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/29788736/evaluation-of-overall-survival-rate-of-different-therapies-in-the-treatment-of-t1-t3-prostate-cancer-a-network-meta-analysis
#4
S Y Chen, Y Du, Q Shao, J S Li, H Y Chen
We performed this network meta-analysis (NMA) in order to compare the overall survival rate of six different therapies of T1-T3 prostate cancer (PC). The therapies include radiotherapy (RT), endocrine therapy (ET), Cryoablation (CRYO), radical prostatectomy (RP), RT+ET and RP+ET. Pubmed, Embase, Cochrane Library, Google Scholar, Web of Science and MEDLINE were searched to collect relevant literature from the inception of the study till February 2017. Cohort studies meeting the inclusion criteria were included in the study...
March 14, 2018: Neoplasma
https://www.readbyqxmd.com/read/29788164/what-is-the-optimal-systemic-treatment-of-men-with-metastatic-hormone-naive-prostate-cancer-a-stopcap-systematic-review-and-network-meta-analysis
#5
C L Vale, D J Fisher, I R White, J R Carpenter, S Burdett, N W Clarke, K Fizazi, G Gravis, N D James, M D Mason, M K B Parmar, L H Rydzewska, C J Sweeney, M R Spears, M R Sydes, J F Tierney
Background: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not zoledronic acid (ZA), were added to androgen-deprivation therapy (ADT). Trial evidence also suggests a benefit of combining celecoxib (Cel) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was carried out based on aggregate data (AD) from all available studies...
May 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29787892/the-role-of-bisphosphonates-or-denosumab-in-light-of-the-availability-of-new-therapies-for-prostate-cancer
#6
REVIEW
Fred Saad, Cora N Sternberg, Peter F A Mulders, Daniela Niepel, Bertrand F Tombal
Most men with advanced prostate cancer will develop bone metastases, which have a substantial impact on quality of life. Bone metastases can lead to skeletal-related events (SREs), which place a burden on patients and healthcare systems. For men with castration-resistant prostate cancer (CRPC) and bone metastases, the treatment landscape has evolved rapidly over the past few years. The relatively recent approvals of the hormonal agents abiraterone acetate and enzalutamide, second-line chemotherapy cabazitaxel, and the radiopharmaceutical radium-223 dichloride (radium-223), have provided clinicians with a greater choice of treatments...
May 3, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29786848/annual-report-to-the-nation-on-the-status-of-cancer-part-i-national-cancer-statistics
#7
Kathleen A Cronin, Andrew J Lake, Susan Scott, Recinda L Sherman, Anne-Michelle Noone, Nadia Howlader, S Jane Henley, Robert N Anderson, Albert U Firth, Jiemin Ma, Betsy A Kohler, Ahmedin Jemal
BACKGROUND: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States. METHODS: Incidence data were obtained from the CDC-funded and NCI-funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the National Center for Health Statistics National Vital Statistics System...
May 22, 2018: Cancer
https://www.readbyqxmd.com/read/29786792/protocols-for-the-study-of-taxanes-chemosensitivity-in-prostate-cancer
#8
M Luz Flores, Carmen Sáez
Prostate cancer is major cause of cancer-related death among men in Western countries. Locally advanced prostate cancers are treated with castration therapy, which is initially effective, but after months the disease progresses to a hormone-refractory state whose treatment is chemotherapy based on taxanes. Although taxanes improve the survival of patients with castration-resistant prostate cancers, these patients often develop chemotherapy resistance, and new therapeutic strategies are necessary. Taxanes exert their action through interaction with β-tubulin which triggers cell cycle arrest in mitosis and the subsequent induction of the intrinsic apoptotic pathway...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29786788/transplantable-animal-studies-and-whole-body-optical-imaging-in-prostate-carcinoma
#9
Geertje van der Horst, Maaike van der Mark, Henry Cheung, Gabri van der Pluijm
Current treatments of advanced prostate cancer only marginally increase overall survival and can be regarded as predominantly palliative. Hence, there is an urgent need for novel therapeutic strategies for the treatment of primary tumors and, more importantly perhaps, for the prevention of tumor progression and metastasis formation. Clinically relevant preclinical models are therefore urgently needed. An ideal, clinically relevant preclinical model would mimic the genetic and phenotypic changes that occur at the different stages of human prostate cancer progression and subsequent metastasis...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29786784/generation-of-prostate-cancer-patient-derived-xenografts-to-investigate-mechanisms-of-novel-treatments-and-treatment-resistance
#10
Hung-Ming Lam, Holly M Nguyen, Eva Corey
Treatment advances lead to survival benefits of patients with advanced prostate cancer. These treatments are highly efficacious in a subset of patients; however, similarly to other cancers, after initial responses the tumors develop resistance (acquired resistance) and the patients succumb to the disease. Furthermore, there is a subset of patients who do not respond to the treatment at all (de novo resistance). Preclinical testing using patient-derived xenografts (PDXs) has led to successful drug development, and PDXs will continue to provide valuable resources to generate clinically relevant data with translational potential...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29785515/prostate-specific-antigen-flare-induced-by-223-racl-2-in-patients-with-metastatic-castration-resistant-prostate-cancer
#11
Angelo Castello, H A Macapinlac, E Lopci, E B Santos
PURPOSE: Prostate-specific antigen (PSA) flare is a well-known phenomenon in patients with prostate cancer, but its impact during radium-223 dichloride (223 RaCl2 ) therapy is still unclear. This radioisotope has shown to improve overall survival in metastatic castration-resistant prostate cancer (mCRPC). We sought to evaluate the impact of PSA flare on survival and its relation with metabolic parameters on 18 F-labeled sodium fluoride PET/CT. METHODS: We conducted a retrospective study of 168 patients with mCRPC (median age 69; median PSA 29...
May 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29785140/do-additional-cores-from-cancer-suspicious-lesions-on-transrectal-ultrasound-improve-prostate-cancer-detection-including-index-tumors-over-12-core-systematic-biopsy
#12
Jung Ki Jo, Sung Kyu Hong, Seok-Soo Byun, Sang Eun Lee, Seong Jin Jeong
Objective: The efficacy of additional cores from cancer-suspicious lesions by transrectal ultrasound (TRUS) for the detection of prostate cancer (PCa) was assessed. Materials and methods: Data were collected from 4144 men who underwent systematic 12-core biopsy with no cancer-suspicious lesions (Group A: 3256 cases) or 13- or more-core (systematic 12 core + additional cores) biopsy with cancer-suspicious lesions (Group B: 888 cases) on TRUS-guided biopsy. The effect of additional biopsy cores on the cancer detection rate was investigated...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29783551/re-long-term-survival-of-patients-aged-80-years-or-older-treated-with-radical-prostatectomy-for-prostate-cancer
#13
Tomas L Griebling
No abstract text is available yet for this article.
June 2018: Journal of Urology
https://www.readbyqxmd.com/read/29782499/tgf%C3%AE-signaling-limits-lineage-plasticity-in-prostate-cancer
#14
Yi Hao, Glen A Bjerke, Karolina Pietrzak, Tiffany A Melhuish, Yu Han, Stephen D Turner, Henry F Frierson, David Wotton
Although treatment options for localized prostate cancer (CaP) are initially effective, the five-year survival for metastatic CaP is below 30%. Mutation or deletion of the PTEN tumor suppressor is a frequent event in metastatic CaP, and inactivation of the transforming growth factor (TGF) ß signaling pathway is associated with more advanced disease. We previously demonstrated that mouse models of CaP based on inactivation of Pten and the TGFß type II receptor (Tgfbr2) rapidly become invasive and metastatic...
May 21, 2018: PLoS Genetics
https://www.readbyqxmd.com/read/29781343/issues-and-promises-of-bevacizumab-in-prostate-cancer-treatment
#15
Vittore Cereda, Vincenzo Formica, Mario Roselli
There is general agreement that increased angiogenesis is an important factor in determining prostate cancer development and prognosis. Vascular Endothelial Growth Factor (VEGF) is thought to play a primary role in the molecular events that lead to prostate cancer progression, from androgen-dependency to castration-resistance until dissemination to the skeleton. Bevacizumab is a recombinant anti-VEGF monoclonal antibody that has exhibited clinical activity in different cancer types. Areas covered: In this review we summarize the data of clinical trials, investigating the effects of bevacizumab in prostate cancer patients...
May 21, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29778323/is-there-a-flare-phenomenon-on-bone-scintigraphy-in-men-with-advanced-prostate-cancer-treated-with-radium-223
#16
Gesa Isensee, Anne Péporté, Joachim Müller, Sabine Schmid, Silke Gillessen, Aurelius Omlin
INTRODUCTION: Radium-223 is an approved survival-prolonging treatment option in men with castration-resistant prostate cancer (mCRPC) and bone metastases. In the registration trial (ALSYMPCA), no regular imaging was mandated. We aimed to analyze men with metastatic mCRPC treated with radium-223 who had bone scintigraphy for staging and treatment monitoring. PATIENTS AND METHODS: Retrospective chart review was performed of mCRPC patients who received 6 cycles of radium-223 and who underwent bone scintigraphy before start of radium-223 and after 3 and 6 cycles of treatment...
April 23, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29774450/the-burden-of-prostate-cancer-in-trinidad-and-tobago-one-of-the-highest-mortality-rates-in-the-world
#17
Wayne A Warner, Tammy Y Lee, Fang Fang, Adana A M Llanos, Smriti Bajracharya, Vasavi Sundaram, Kimberly Badal, Vandana Devika Sookdeo, Veronica Roach, Marjorie Lamont-Greene, Camille Ragin, Simeon Slovacek, Krishan Ramsoobhag, Jasmine Brown, Timothy R Rebbeck, Ravi Maharaj, Bettina F Drake
PURPOSE: In Trinidad and Tobago (TT), prostate cancer (CaP) is the most commonly diagnosed malignancy and the leading cause of cancer deaths among men. TT currently has one of the highest CaP mortality rates in the world. METHODS: 6,064 incident and 3,704 mortality cases of CaP occurring in TT from January 1995 to 31 December 2009 reported to the Dr. Elizabeth Quamina Cancer population-based cancer registry for TT, were analyzed to examine CaP survival, incidence, and mortality rates and trends by ancestry and geography...
May 17, 2018: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/29773955/survival-outcomes-of-radical-prostatectomy-and-external-beam-radiotherapy-in-clinically-localized-high-risk-prostate-cancer-a-population-based-propensity-score-matched-study
#18
Xiaobin Gu, Xianshu Gao, Ming Cui, Mu Xie, Mingwei Ma, Shangbin Qin, Xiaoying Li, Xin Qi, Yun Bai, Dian Wang
Objective: This study was aimed to compare survival outcomes in high-risk prostate cancer (PCa) patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP). Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify PCa patients with high-risk features who received RP alone or EBRT alone from 2004 to 2008. Propensity-score matching (PSM) was performed. Kaplan-Meier survival analysis was used to compare cancer-specific survival (CSS) and overall survival (OS)...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29772102/novel-nomograms-for-castration-resistant-prostate-cancer-and-survival-outcome-in-patients-with-de-novo-bone-metastatic-prostate-cancer
#19
Jinge Zhao, Guangxi Sun, Banghua Liao, Xingming Zhang, Cameron M Armstrong, Xiaoxue Yin, Jiandong Liu, Junru Chen, Yaojing Yang, Peng Zhao, Qidun Tang, Zhenghao Wang, Zhibin Chen, Xiong Li, Qiang Wei, Xiang Li, Ni Chen, Allen C Gao, Pengfei Shen, Hao Zeng
OBJECTIVES: To develop nomograms predicting the incidence of castration resistant prostate cancer (CRPC) and overall survival (OS) for de novo metastatic prostate cancer (mPCa). MATERIALS AND METHODS: Data from 449 de novo mPCa patients were retrospectively analyzed. Patients were randomly divided into the training (n=314, 70%) and validation cohort (n=135, 30%). Predictive factors were selected by Cox-proportional model and further used for building predictive models...
May 17, 2018: BJU International
https://www.readbyqxmd.com/read/29772100/radical-prostatectomy-in-t4-prostate-cancer-after-inductive-androgen-deprivation-results-of-a-single-institution-series-with-long-term-follow-up
#20
Turkan Hajili, Carsten H Ohlmann, Johannes Linxweiler, Christina Niklas, Martin Janssen, Stefan Siemer, Michael Stoeckle, Matthias Saar
OBJECTIVES: To determine the outcomes of complete surgical resection of T4 prostate cancer (PCa) after inductive androgen deprivation treatment (ADT). An inductive ADT and subsequent radical prostatectomy (RP) is not recommended by any guideline yet. PATIENTS AND METHODS: A monocentric RP database was queried for patients initially diagnosed with T4 PCa, considered as primary inoperable because of a fixed mass defined by rectal examination in combination with high PSA and/or large foci of biopsy-proven undifferentiated PCa...
May 17, 2018: BJU International
keyword
keyword
8536
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"